| Q34766538 | 5-HT2C ligands: recent progress |
| Q33939074 | A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis |
| Q42745495 | A novel and integrated approach for the identification and characterization of drug-induced cardiac toxicity in the dog. |
| Q37950014 | A review of the use of in silico methods to predict the chemistry of molecular initiating events related to drug toxicity |
| Q47938563 | A role for the autophagy regulator Transcription Factor EB in amiodarone-induced phospholipidosis |
| Q38594358 | Amphiphilic drug interactions with model cellular membranes are influenced by lipid chain-melting temperature |
| Q58608409 | An Expandable Mechanopharmaceutical Device (3): a Versatile Raman Spectral Cytometry Approach to Study the Drug Cargo Capacity of Individual Macrophages |
| Q38618764 | An Immunohistochemical Investigation of Renal Phospholipidosis and Toxicity in Rats |
| Q28278771 | Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities |
| Q38122934 | Chitosans for delivery of nucleic acids. |
| Q28257881 | Comparison of the diagnostic accuracy of di-22:6-bis(monoacylglycerol)phosphate and other urinary phospholipids for drug-induced phospholipidosis or tissue injury in the rat |
| Q38732067 | Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitors |
| Q39541065 | Construction and Consensus Performance of (Q)SAR Models for Predicting Phospholipidosis Using a Dataset of 743 Compounds |
| Q34977885 | Detection of phospholipidosis induction: a cell-based assay in high-throughput and high-content format. |
| Q39374963 | Differential cytotoxicity responses by dog and rat hepatocytes to phospholipogenic treatments. |
| Q37547214 | Do nanomedicines require novel safety assessments to ensure their safety for long-term human use? |
| Q50507423 | Dose- and Time-dependency of the Toxicity and Pharmacokinetic Profiles of Bedaquiline and Its N-desmethyl Metabolite in Dogs. |
| Q37829433 | Drug and metabolite concentrations in tissues in relationship to tissue adverse findings: a review |
| Q59489001 | Evaluating the risk of phospholipidosis using a new multidisciplinary pipeline approach |
| Q33633614 | Extending pKa prediction accuracy: high-throughput pKa measurements to understand pKa modulation of new chemical series |
| Q38793908 | High Content Analysis of Human Pluripotent Stem Cell Derived Hepatocytes Reveals Drug Induced Steatosis and Phospholipidosis |
| Q38383132 | High-content screening technology for studying drug-induced hepatotoxicity in cell models. |
| Q30560958 | Identification of drugs inducing phospholipidosis by novel in vitro data |
| Q33686976 | Identification of hepatic phospholipidosis inducers in sandwich-cultured rat hepatocytes, a physiologically relevant model, reveals altered basolateral uptake and biliary excretion of anionic probe substrates |
| Q34596668 | Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection |
| Q36234390 | In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383 |
| Q36609748 | In vitro assays and biomarkers for drug-induced phospholipidosis |
| Q91715341 | Insight into the Role of Extracellular Vesicles in Lysosomal Storage Disorders |
| Q83137944 | Interaction of gentamicin with phosphatidylserine/phosphatidylcholine mixtures in adsorption monolayers and thin liquid films: morphology and thermodynamic properties |
| Q41973216 | Intracellular sequestration of amiodarone: role of vacuolar ATPase and macroautophagic transition of the resulting vacuolar cytopathology. |
| Q39260081 | Is It Adverse, Nonadverse, Adaptive, or Artifact? |
| Q36985063 | Kinetic determinants of hepatic clearance: plasma protein binding and hepatic uptake |
| Q34726610 | Mechanisms of Amine Accumulation in, and Egress from, Lysosomes |
| Q64071287 | Metabolic disease and ABHD6 alter the circulating bis(monoacylglycerol)phosphate profile in mice and humans |
| Q58137081 | Modeling Phospholipidosis Induction: Reliability and Warnings |
| Q38468007 | Molecular biomarkers of phospholipidosis in rat blood and heart after amiodarone treatment |
| Q24635290 | Molecular imaging of intracellular drug-membrane aggregate formation |
| Q36667157 | Multiscale distribution and bioaccumulation analysis of clofazimine reveals a massive immune system-mediated xenobiotic sequestration response |
| Q30841407 | New insights into the intracellular distribution pattern of cationic amphiphilic drugs |
| Q26766096 | Nonproliferative and Proliferative Lesions of the Gastrointestinal Tract, Pancreas and Salivary Glands of the Rat and Mouse |
| Q38890510 | Occupational Asthma Due to Inhalation of Aerosolized Lipophilic Coating Materials |
| Q37723945 | Pathology and Neurotoxicity in Dogs after Repeat Dose Exposure to a Serotonin 5-HT1B Inhibitor |
| Q53344751 | Phospholipidosis effect of drugs by adsorption into lipid monolayers. |
| Q39625030 | Phospholipidosis induced by PPARγ signaling in human bronchial epithelial (BEAS-2B) cells exposed to amiodarone |
| Q42213351 | Phospholipogenic pharmaceuticals are associated with a higher incidence of histological findings than nonphospholipogenic pharmaceuticals in preclinical toxicology studies |
| Q33845886 | Physicochemical drug properties associated with in vivo toxicological outcomes: a review |
| Q33880158 | Proceedings of the 2015 National Toxicology Program Satellite Symposium. |
| Q37824547 | Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary system |
| Q47446772 | ProxyPhos sensors for the detection of negatively charged membranes |
| Q43269144 | Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats |
| Q39369271 | Renal phospholipidosis possibly induced by ranolazine |
| Q35827839 | Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. |
| Q37529605 | Screening for the drug-phospholipid interaction: correlation to phospholipidosis |
| Q59488951 | Synthesis and phospholipidosis effect of a series of cationic amphiphilic compounds: a case study to evaluate in silico and in vitro assays |
| Q36887542 | The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates |
| Q38651282 | The chemical, genetic and immunological basis of idiosyncratic drug-induced liver injury. |
| Q37999093 | The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery |
| Q82067204 | Tissue Distribution and Characterization of Drug-Related Material in Rats and Dogs after Repeated Oral Administration of Casopitant |
| Q37554404 | Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring |
| Q38944440 | Toward a unifying strategy for the structure-based prediction of toxicological endpoints |
| Q34244280 | Ultrastructural analysis in preclinical safety evaluation |
| Q38346812 | Use of read-across and computer-based predictive analysis for the safety assessment of PEG cocamines |
| Q38842510 | Use of the Distribution Coefficient in Brain Polar Lipids for the Assessment of Drug-Induced Phospholipidosis Risk |